Canadian Consensus Recommendations on the Management of MET-Altered NSCLC

Current Oncology

Shantanu O. Banerji¹  Quincy S.-C. Chu²  Brandon S. Sheffield³  Barbara L. Melosky⁴  Rosalyn A. Juergens⁵  Normand Blais⁶  Paul F. Wheatley-Price⁷  Parneet K. Cheema⁸  Natasha B. Leighl⁹  Patrice Desmeules^1,10 

[1] CancerCare Manitoba Research Institute, Department of Medical Oncology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB R3E 0V9, Canada;Cross Cancer Institute, Alberta Health Services, Edmonton, AB T6G 1Z2, Canada;Department of Laboratory Medicine, William Osler Health System, Brampton, ON L6R 3J7, Canada;Department of Medical Oncology, BC Cancer-Vancouver Centre, Vancouver, BC V5Z 4E6, Canada;Department of Medical Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada;Department of Medicine, Centre Hospitalier de l’Université de Montréal, University of Montreal, Montreal, QC H2X 3E4, Canada;Department of Medicine, The Ottawa Hospital Research Institute, The Ottawa Hospital, University of Ottawa, Ottawa, ON K1H 8L6, Canada;Medical Oncology/Hematology, William Osler Health System, Brampton, ON L6R 3J7, Canada;Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada;Service d’Anatomopathologie et de Cytologie, Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, QC G1V 0A6, Canada;

关键词: non-small cell lung cancer;    MET exon 14 skipping mutations;    MET amplification;    MET inhibitors;    EGFR resistance;   

DOI  :  10.3390/curroncol28060386

来源: DOAJ

【 摘 要 】

In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatments. These variations, together with the emergence of several novel mesenchymal-epithelial transition (MET) factor-targeted therapies for the treatment of NSCLC, warrant the development of evidence-based consensus recommendations for the use of these agents. A Canadian expert panel was convened to define key clinical questions, review evidence, discuss practice recommendations and reach consensus on the treatment of advanced MET-altered NSCLC. Questions addressed by the panel include: 1. How should the patients most likely to benefit from MET-targeted therapies be identified? 2. What are the preferred first-line and subsequent therapies for patients with MET exon 14 skipping mutations? 3. What are the preferred first-line and subsequent therapies for advanced NSCLC patients with de novo MET amplification? 4. What is the preferred therapy for patients with advanced epidermal growth factor receptor (EGFR)-mutated NSCLC with acquired MET amplification progressing on EGFR inhibitors? 5. What are the potential strategies for overcoming resistance to MET inhibitors? Answers to these questions, along with the consensus recommendations herein, will help streamline the management of MET-altered NSCLC in routine practice, assist clinicians in therapeutic decision-making, and help ensure optimal outcomes for NSCLC patients with MET alterations.

【 授权许可】

Unknown